AMAG Pharmaceuticals, Inc. to Present at
Upcoming Investor Conferences
September 07, 2010 04:08 PM Eastern Daylight Time
LEXINGTON, Mass.--(EON: Enhanced Online News)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)
today announced that management will present an overview of the company at the following investor conferences
during the month of September:
l Morgan Stanley Global Healthcare Unplugged Conference on September 13 at 1:35 p.m. ET
l Robert W. Baird 2010 Healthcare Conference on September 14, at 9:30 a.m. ET
l UBS 2010 Global Life Sciences Conference on September 22, at 2:00 p.m. ET
The conferences are being held in New York City.
A live webcast of each presentation will be accessible through the Investors section of the company’s website at
www.amagpharma.com. Following each conference, the webcast will be archived on the AMAG Pharmaceuticals,
Inc. website for approximately two weeks.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the
development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG manufactures and sells two
commercial products, Feraheme® (ferumoxytol) Injection for intravenous (IV) use and GastroMARK®, an oral
contrast agent used in magnetic resonance imaging. For additional company information, please visit
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361